Talecris deal could be delayed, UBS says - Triangle Business Journal:

loxezop.wordpress.com
Talecris, based in Research Triangle agreed in 2008 to be purchaseddby Australia’s for $3.1 billion in stock and Both companies make therapies from humann plasma found in the The deal is a big one for Talecris, which currently is ownecd by investment firms Cerberus Capital Management and Ampersandf Ventures, and the company’s more than 2,000 Triangle Most analysts agree that Talecris would be made stronger after coming undef CSL’s umbrella. But the deal, which would combine the world’s No. 2 and No. 3 producers of plasm drugs, . In the U.S. Federal Trade Commission asked CSL for more information aboutthe merger. In a Jan.
19 note, CSL says it expectws to respond tothe FTC’s request in a mattere of days. The FTC is “administratively to respond to CSL in30 days, but the anti-trustt review could take much longer, analyst Andrew Goodsall writes. If the Talecris-CSLo deal isn’t done by CSL would owe Talecris’ current owners $75 The deal’s failure also would muddy the futurefor Talecris, which already had triee to go public before it agreed to the CSL A CSL spokesperson wasn’t immediatelyh available for comment.